Overview

Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease

Status:
Not yet recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled study in sickle cell disease participants with a history of Vaso-occlusive Crises (VOCs). Approximately 60 participants with sickle cell disease will be enrolled and randomized: 12 participants in each of four active novel formulation rifaximin groups and 6 participants in each of 2 placebo groups.

Phase:

Phase 2

Details

Lead Sponsor:

Bausch Health Americas, Inc.

Treatments:

Rifaximin